Nanjing Well Pharmaceutical Co Ltd (603351) — Capital Reinvestment Ratio
Nanjing Well Pharmaceutical Co Ltd (603351) has a Capital Reinvestment Ratio of 0.15x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥69.51 Million) in capital expenditures (CN¥10.29 Million). See 603351 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Well Pharmaceutical Co Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Nanjing Well Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Nanjing Well Pharmaceutical Co Ltd from 2014 to 2024. For live market cap and broader valuation context, see how much is Nanjing Well Pharmaceutical Co Ltd worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.23x | CN¥221.79 Million | CN¥51.46 Million | ▼ -61.8% |
| 2023 | 0.61x | CN¥120.24 Million | CN¥73.07 Million | ▼ -71.7% |
| 2022 | 2.15x | CN¥108.99 Million | CN¥233.90 Million | ▼ -29.1% |
| 2020 | 3.03x | CN¥93.30 Million | CN¥282.44 Million | ▲ +225.5% |
| 2019 | 0.93x | CN¥129.69 Million | CN¥120.62 Million | ▼ -22.9% |
| 2018 | 1.21x | CN¥63.76 Million | CN¥76.95 Million | ▲ +35.8% |
| 2017 | 0.89x | CN¥71.27 Million | CN¥63.35 Million | ▲ +64.4% |
| 2016 | 0.54x | CN¥128.18 Million | CN¥69.31 Million | ▼ -43.0% |
| 2015 | 0.95x | CN¥81.14 Million | CN¥76.92 Million | ▼ -20.1% |
| 2014 | 1.19x | CN¥74.62 Million | CN¥88.54 Million | — |